Diabetes Prevention Program results are now published

[Kuester, Sarah]

Please pardon any cross-posting.
Hello.  Below is an NIDDK press release announcing the results of the
Diabetes Prevention Program published this week in the New England Journal
of Medicine.  See http://content.nejm.org/ for a copy of the abstract.  The
citation for the article is:
Diabetes Prevention Program Research Group. Reduction in the Incidence of
Type 2 Diabetes with Lifestyle Intervention or Metformin
February 7, 2002, NEJM, Volume 346(6):393-403.

Thank you,
Sarah Kuester
Public Health Nutritionist
Centers for Disease Control and Prevention
sak2 at cdc.gov 
-----------------------------------------------------------------------
Source: http://www.niddk.nih.gov/welcome/releases/02-06-02.htm
February 6, 2002
Diet and Exercise Delay Diabetes and Normalize Blood Glucose
Millions of overweight Americans at high risk for type 2 diabetes can delay
and possibly prevent the disease with moderate diet and exercise, a major
clinical trial has found. The same study found that the oral diabetes drug
metformin (Glucophage) also reduces type 2 diabetes risk, although not as
effectively as lifestyle changes. Researchers announced results of the
trial, called the Diabetes Prevention Program (DPP), last August after
ending the study a year early. The study results are reported in the
February 7 issue of the New England Journal of Medicine.
"This research conveys a powerful message of hope to individuals at risk for
type 2 diabetes, a painful, life-threatening disease that has been
increasing in this country along with obesity," said HHS Secretary Tommy G.
Thompson. "By adopting a moderate, consistent diet and exercise program,
many people with one or more of the risk factors for type 2 diabetes can
stop the disease before it becomes irreversible." 
The DPP compared three approaches--lifestyle modification, treatment with
metformin, and standard medical advice--in 3,234 overweight people with
impaired glucose tolerance (IGT), a condition in which blood glucose levels
are higher than normal but not yet diabetic. About 20 million people in the
United States have IGT, which raises the risk of developing type 2 diabetes
and cardiovascular disease. Once a person has type 2 diabetes, the risk of
heart and blood vessel disease is even greater-2 to 4 times that of people
without diabetes.
Diet and exercise that achieved a 5- to 7-percent weight loss reduced
diabetes incidence by 58 percent in participants randomized to the study's
lifestyle intervention group. Participants in this group exercised at
moderate intensity, usually by walking an average of 30 minutes a day five
days a week, and lowered their intake of fat and calories. Volunteers
randomly assigned to treatment with metformin had a 31 percent lower
incidence of type 2 diabetes. Metformin lowers blood glucose mainly by
decreasing the liver's production of glucose.
"Lifestyle intervention worked equally well in men and women and in all the
ethnic groups. It was most effective in people age 60 and older, who lowered
the risk of developing diabetes by 71 percent. Metformin was also effective
in both sexes and in all the ethnic groups, but it was relatively
ineffective in older volunteers and in those who were less overweight," said
study chair Dr. David Nathan of Massachusetts General Hospital, Boston.
Both interventions lowered fasting blood glucose levels, but lifestyle
changes more effectively lowered blood glucose levels 2 hours after a
glucose drink. Also, about twice as many people in the lifestyle group
compared to placebo regained normal glucose tolerance, showing that diet and
exercise can reverse IGT.
"Not only did changes in diet and physical activity prevent or delay the
development of diabetes, they actually restored normal glucose levels in
many people who had impaired glucose tolerance," said Dr. Allen Spiegel,
director of the National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), the part of the National Institutes of Health (NIH) that
sponsored the study. "These findings bring us closer to the goal of
containing and ultimately reversing the epidemic of type 2 diabetes in this
country." 
DPP volunteers were randomly assigned to one of the following groups: 
*	lifestyle modification with the aim of reducing weight by 7 percent
through a low-fat diet and exercising for 150 minutes a week. 
*	treatment with the drug metformin (850 mg twice a day), approved in
1995 to treat type 2 diabetes. 
*	a standard group taking placebo pills in place of metformin. 
The latter two groups also received information on diet and exercise. 
A fourth arm of the study, treatment with the drug troglitazone (Rezulin)
combined with standard diet and exercise recommendations, was discontinued
in June 1998 due to the potential for liver toxicity.
DPP participants ranged from age 25 to 85, with an average age of 51. Upon
entering the study, all had impaired glucose tolerance as measured by an
oral glucose tolerance test, and all were overweight, with an average body
mass index (BMI) of 34. About 29 percent of the DPP standard group developed
diabetes during the average follow-up period of 3 years. In contrast, 14
percent of the diet and exercise arm and 22 percent of the metformin group
developed diabetes. Volunteers in the diet and exercise arm met the study
goal, on average a 7 percent--or 15-pound--weight loss, in the first year
and generally sustained a 5 percent total loss for the study's duration.
Participants in the lifestyle intervention arm received training in diet,
exercise (most chose walking), and behavior modification skills. (See also
Diabetes Prevention Program: Questions & Answers
http://www.niddk.nih.gov/patient/dpp/dpp-q&a.htm).
Forty-five percent of DPP participants were from minority groups that suffer
disproportionately from type 2 diabetes: African Americans, Hispanic
Americans, Asian Americans and Pacific Islanders, and American Indians. The
trial also recruited other groups at higher risk for type 2 diabetes,
including individuals age 60 and older, women with a history of gestational
diabetes, and people with a first-degree relative with type 2 diabetes.
Can the interventions prevent diabetes completely? "We simply don't know how
long, beyond the 3-year period studied, diabetes can be delayed," says Dr.
Nathan. "We hope to follow the DPP volunteers to learn how long the
interventions are effective." The researchers will analyze the data to
determine whether the interventions reduced cardiovascular disease and
atherosclerosis, major causes of death in people with type 2 diabetes.
Other studies have shown that diet and exercise delay type 2 diabetes in
at-risk people. However, the DPP, conducted at 27 centers nationwide, is the
first major trial to show that lifestyle changes can effectively delay
diabetes in a diverse population of overweight American adults with impaired
glucose tolerance.
About 16 million people in the United States have diabetes. It is the main
cause of kidney failure, limb amputations, and new onset blindness in adults
and a major cause of heart disease and stroke. Type 2 diabetes accounts for
up to 95 percent of all diabetes cases. Most common in adults over age 40,
type 2 diabetes affects 8 percent of the U.S. population age 20 and older.
It is strongly associated with obesity (more than 80 percent of people with
type 2 diabetes are overweight), inactivity, family history of diabetes, and
racial or ethnic background. The prevalence of type 2 diabetes has tripled
in the last 30 years, due in large part to the upsurge in obesity. People
with a BMI of 30 or greater have a five-fold greater risk of diabetes than
those with a normal BMI of 25 or less.
The DPP was funded by a number of HHS agencies: the National Institute of
Diabetes and Digestive and Kidney Diseases, the National Institute of Child
Health and Human Development, the National Institute on Aging, the National
Center on Minority Health and Health Disparities, the National Center for
Research Resources, the Office of Research on Women's Health, and the Office
of Behavioral and Social Science Research within the NIH as well as the
Centers for Disease Control and Prevention and the Indian Health Service.
The American Diabetes Association provided additional funding. Sources of
corporate support included Bristol-Myers Squibb, Parke-Davis, Merck and
Company, Merck Medco, Hoechst Marion Roussel, Sankyo, Lifescan, Slimfast,
Nike, and Health-O-Meter.
Contacts:
NIDDK (301) 496-3583
Joan Chamberlain
Jane DeMouy